Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Climb Bio, Inc. (CLYM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13,93, with a market capitalisation of $836,27M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,54 to $18,33. This page covers its latest market performance, valuation, price trends and company information.
$836,27M | |
$13,93 | |
$18,33 | |
$1,05 | |
$13,91 | |
11,00 | |
1,42M | |
-- | |
$18,33 | |
$1,54 | |
-- | |
-- |
Climb Bio, Inc. (CLYM) is trading at $13,93 in pre-market trading as of 2026-09-16 09:34:00, up 0,14% ($0,02) from the previous close of $13,91
Pre-market trading shows how investors are pricing CLYM before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Climb Bio, Inc. (CLYM) moved from $15,52 to $13,93, representing a decline of 10,24% ($1,59).
The stock traded between $13,38 and $16,17 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1,37 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 73,8%
CLYM is currently trading at $13,93, placing it 73,8% of the way from its 52-week low of $1,54 to its 52-week high of $18,33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Climb Bio, Inc. (CLYM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.